Transcatheter aortic valve replacement outcomes in mixed aortic valve disease compared to predominant aortic stenosis

Behnam Heidari, Mohammed A. Al-Hijji, Mohamad A. Alkhouli, Alexander Egbe, Garrett Welle, Mackram Eleid, Mandeep Singh, Rajiv Gulati, Charanjit Rihal, Amir Lerman

Research output: Contribution to journalArticle

Abstract

Background: MAVD, defined as severe aortic stenosis with moderate or severe aortic regurgitation, is frequently encountered in clinical practice. However, the data regarding TAVR outcomes in MAVD are sparse. We compared Transcatheter Aortic Valve Replacement (TAVR) outcomes between Mixed Aortic Valve Disease (MAVD) and Predominant Aortic Stenosis (PAS) patients. Methods: Patients who underwent TAVR at Mayo Clinic from February 7, 2012 to December 16, 2016 were enrolled. The primary end point was all-cause mortality. Secondary end points were central or paravalvular regurgitation, device success, and Valve Academic Research Consortium (VARC)-2 defined post TAVR complications (access site complications, bleedings, myocardial infarction, stroke, and cardiac arrest). Results: A total of 622 patients were enrolled. Mean age was 81 ± 8.9 years, and 263 (42.3%) were female. Median follow-up duration was 1.5 years. One hundred and sixteen patients (18.6%) had MAVD. Central or paravalvular leak was higher in MAVD patients post-TAVR (15.5% vs 6.7%, P = 0.004). Device success and VARC-2 in-hospital complications were similar between the two groups. The cumulative probability of survival at 3 years was 71.3% in MAVD patients vs. 62.6% in PAS patients (Log-Rank P = 0.024). In a multi-variant logistic regression analysis, MAVD was an independent negative predictor of all-cause mortality (HR = 0.53, 95% CI 0.3–0.89, P = 0.015). Conclusions: A significant number of patients referred for TAVR have MAVD disease. Despite higher rates of paravalvular regurgitation, all-cause mortality at mid-term was lower in patients with MAVD compared with those with PAS. Our results show the safety and efficacy of TAVR in MAVD patients.

Original languageEnglish (US)
JournalInternational Journal of Cardiology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Aortic Diseases
Aortic Valve Stenosis
Aortic Valve
Mortality
Transcatheter Aortic Valve Replacement
Equipment and Supplies
Aortic Valve Insufficiency
Heart Arrest
Research
Logistic Models
Stroke
Myocardial Infarction
Regression Analysis
Hemorrhage
Safety

Keywords

  • Aortic regurgitation
  • Aortic stenosis
  • Heart valve diseases
  • Mixed aortic valve disease
  • Transcatheter aortic valve replacement

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Transcatheter aortic valve replacement outcomes in mixed aortic valve disease compared to predominant aortic stenosis. / Heidari, Behnam; Al-Hijji, Mohammed A.; Alkhouli, Mohamad A.; Egbe, Alexander; Welle, Garrett; Eleid, Mackram; Singh, Mandeep; Gulati, Rajiv; Rihal, Charanjit; Lerman, Amir.

In: International Journal of Cardiology, 01.01.2019.

Research output: Contribution to journalArticle

@article{ad85d0502374412590e6303d83651248,
title = "Transcatheter aortic valve replacement outcomes in mixed aortic valve disease compared to predominant aortic stenosis",
abstract = "Background: MAVD, defined as severe aortic stenosis with moderate or severe aortic regurgitation, is frequently encountered in clinical practice. However, the data regarding TAVR outcomes in MAVD are sparse. We compared Transcatheter Aortic Valve Replacement (TAVR) outcomes between Mixed Aortic Valve Disease (MAVD) and Predominant Aortic Stenosis (PAS) patients. Methods: Patients who underwent TAVR at Mayo Clinic from February 7, 2012 to December 16, 2016 were enrolled. The primary end point was all-cause mortality. Secondary end points were central or paravalvular regurgitation, device success, and Valve Academic Research Consortium (VARC)-2 defined post TAVR complications (access site complications, bleedings, myocardial infarction, stroke, and cardiac arrest). Results: A total of 622 patients were enrolled. Mean age was 81 ± 8.9 years, and 263 (42.3{\%}) were female. Median follow-up duration was 1.5 years. One hundred and sixteen patients (18.6{\%}) had MAVD. Central or paravalvular leak was higher in MAVD patients post-TAVR (15.5{\%} vs 6.7{\%}, P = 0.004). Device success and VARC-2 in-hospital complications were similar between the two groups. The cumulative probability of survival at 3 years was 71.3{\%} in MAVD patients vs. 62.6{\%} in PAS patients (Log-Rank P = 0.024). In a multi-variant logistic regression analysis, MAVD was an independent negative predictor of all-cause mortality (HR = 0.53, 95{\%} CI 0.3–0.89, P = 0.015). Conclusions: A significant number of patients referred for TAVR have MAVD disease. Despite higher rates of paravalvular regurgitation, all-cause mortality at mid-term was lower in patients with MAVD compared with those with PAS. Our results show the safety and efficacy of TAVR in MAVD patients.",
keywords = "Aortic regurgitation, Aortic stenosis, Heart valve diseases, Mixed aortic valve disease, Transcatheter aortic valve replacement",
author = "Behnam Heidari and Al-Hijji, {Mohammed A.} and Alkhouli, {Mohamad A.} and Alexander Egbe and Garrett Welle and Mackram Eleid and Mandeep Singh and Rajiv Gulati and Charanjit Rihal and Amir Lerman",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ijcard.2019.07.099",
language = "English (US)",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Transcatheter aortic valve replacement outcomes in mixed aortic valve disease compared to predominant aortic stenosis

AU - Heidari, Behnam

AU - Al-Hijji, Mohammed A.

AU - Alkhouli, Mohamad A.

AU - Egbe, Alexander

AU - Welle, Garrett

AU - Eleid, Mackram

AU - Singh, Mandeep

AU - Gulati, Rajiv

AU - Rihal, Charanjit

AU - Lerman, Amir

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: MAVD, defined as severe aortic stenosis with moderate or severe aortic regurgitation, is frequently encountered in clinical practice. However, the data regarding TAVR outcomes in MAVD are sparse. We compared Transcatheter Aortic Valve Replacement (TAVR) outcomes between Mixed Aortic Valve Disease (MAVD) and Predominant Aortic Stenosis (PAS) patients. Methods: Patients who underwent TAVR at Mayo Clinic from February 7, 2012 to December 16, 2016 were enrolled. The primary end point was all-cause mortality. Secondary end points were central or paravalvular regurgitation, device success, and Valve Academic Research Consortium (VARC)-2 defined post TAVR complications (access site complications, bleedings, myocardial infarction, stroke, and cardiac arrest). Results: A total of 622 patients were enrolled. Mean age was 81 ± 8.9 years, and 263 (42.3%) were female. Median follow-up duration was 1.5 years. One hundred and sixteen patients (18.6%) had MAVD. Central or paravalvular leak was higher in MAVD patients post-TAVR (15.5% vs 6.7%, P = 0.004). Device success and VARC-2 in-hospital complications were similar between the two groups. The cumulative probability of survival at 3 years was 71.3% in MAVD patients vs. 62.6% in PAS patients (Log-Rank P = 0.024). In a multi-variant logistic regression analysis, MAVD was an independent negative predictor of all-cause mortality (HR = 0.53, 95% CI 0.3–0.89, P = 0.015). Conclusions: A significant number of patients referred for TAVR have MAVD disease. Despite higher rates of paravalvular regurgitation, all-cause mortality at mid-term was lower in patients with MAVD compared with those with PAS. Our results show the safety and efficacy of TAVR in MAVD patients.

AB - Background: MAVD, defined as severe aortic stenosis with moderate or severe aortic regurgitation, is frequently encountered in clinical practice. However, the data regarding TAVR outcomes in MAVD are sparse. We compared Transcatheter Aortic Valve Replacement (TAVR) outcomes between Mixed Aortic Valve Disease (MAVD) and Predominant Aortic Stenosis (PAS) patients. Methods: Patients who underwent TAVR at Mayo Clinic from February 7, 2012 to December 16, 2016 were enrolled. The primary end point was all-cause mortality. Secondary end points were central or paravalvular regurgitation, device success, and Valve Academic Research Consortium (VARC)-2 defined post TAVR complications (access site complications, bleedings, myocardial infarction, stroke, and cardiac arrest). Results: A total of 622 patients were enrolled. Mean age was 81 ± 8.9 years, and 263 (42.3%) were female. Median follow-up duration was 1.5 years. One hundred and sixteen patients (18.6%) had MAVD. Central or paravalvular leak was higher in MAVD patients post-TAVR (15.5% vs 6.7%, P = 0.004). Device success and VARC-2 in-hospital complications were similar between the two groups. The cumulative probability of survival at 3 years was 71.3% in MAVD patients vs. 62.6% in PAS patients (Log-Rank P = 0.024). In a multi-variant logistic regression analysis, MAVD was an independent negative predictor of all-cause mortality (HR = 0.53, 95% CI 0.3–0.89, P = 0.015). Conclusions: A significant number of patients referred for TAVR have MAVD disease. Despite higher rates of paravalvular regurgitation, all-cause mortality at mid-term was lower in patients with MAVD compared with those with PAS. Our results show the safety and efficacy of TAVR in MAVD patients.

KW - Aortic regurgitation

KW - Aortic stenosis

KW - Heart valve diseases

KW - Mixed aortic valve disease

KW - Transcatheter aortic valve replacement

UR - http://www.scopus.com/inward/record.url?scp=85070207342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070207342&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2019.07.099

DO - 10.1016/j.ijcard.2019.07.099

M3 - Article

AN - SCOPUS:85070207342

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -